背景:执行功能,包括前瞻记忆,启动,规划,对日常活动进行排序,经常受到获得性脑损伤(ABI)的影响。执行功能障碍需要使用代偿性认知策略,在更严重的情况下,随着时间的推移,人类的支持。为了弥补所经历的执行功能障碍,有ABI的人及其支持者可能会使用越来越多的电子主流和辅助技术选择。
目的:我们概述了一系列单案例实验设计(SCED)的研究方案,以评估智能家居的有效性,mobile,和/或可穿戴技术在减少ABI之后的执行功能困难。
方法:将在维多利亚州和新南威尔士州招募多达10名患有ABI的成年人,他们经历了执行功能障碍并具有足够的认知能力以提供知情同意。澳大利亚。其他关键的纳入标准是他们对日常生活有大量的支持需求,并居住在社区住宅中。根据参与者确定的目标和目标行为,将选择特定的电子辅助技术进行应用。目标行为的识别和辅助技术的选择将通过与每个参与者(及其关键支持者,如果适用)。SCED的选择将根据干预中使用的技术类型为每个参与者个性化,针对变化的行为的难度级别,以及预期的变化率。对于每个SCED,在基线条件期间对目标行为的重复测量将提供性能数据,用于与在干预条件期间收集的性能数据(引入技术)进行比较。次要结果指标将评估干预措施的影响。该协议包括2个可自定义的MicrosoftExcel电子表格,用于电子记录保存。
结果:招聘期为2022年6月至2024年3月。个体参与者的试验结果将使用结构化的视觉分析和统计分析进行单独的绘图和分析。分析将侧重于数据的重要特征,包括响应水平的阶段内和阶段间比较,趋势,可变性,即时性,一致性,和重叠。探索性经济评估将确定对正式和非正式支持使用的影响,以及生活质量,在实施新技术干预之后。
结论:该研究旨在测试干预措施之间的因果关系功能关系-在这种情况下,电子辅助技术-及其在改变目标行为中的作用。获得的评估证据将为ABI后经历执行功能障碍的人提供各种电子辅助技术应用的新见解。此外,这些结果将有助于提高关键利益相关者的能力,以利用技术的潜力来建立独立性并降低对该人群的护理成本。
背景:澳大利亚新西兰临床试验注册(ANZCTR)ACTRN12622000835741,https://www。anzctr.org.au/ACTRN12622000835741。aspx.
■DERR1-10.2196/48503。
BACKGROUND: Executive function, including prospective memory, initiating, planning, and sequencing everyday activities, is frequently affected by acquired brain injury (ABI). Executive dysfunction necessitates the use of compensatory cognitive strategies and, in more severe cases, human support over time. To compensate for the executive dysfunction experienced, growing options for electronic mainstream and assistive technologies may be used by people with ABI and their supporters.
OBJECTIVE: We outline the study protocol for a series of single-case experimental designs (SCEDs) to evaluate the effectiveness of smart home, mobile, and/or wearable technologies in reducing executive function difficulties following ABI.
METHODS: Up to 10 adults with ABI who experience executive dysfunction and have sufficient cognitive capacity to provide informed consent will be recruited across Victoria and New South Wales, Australia. Other key inclusion criteria are that they have substantial support needs for everyday living and reside in community dwellings. On the basis of the participant\'s identified goal(s) and target behavior(s), a specific electronic assistive technology will be selected for application. Both identification of the target behavior(s) and selection of the assistive technology will be determined via consultation with each participant (and their key support person, if applicable). The choice of SCED will be individualized for each participant based on the type of technology used in the intervention, the difficulty level of the behavior targeted for change, and the anticipated rate of change. For each SCED, repeated measurements of the target behavior(s) during the baseline condition will provide performance data for comparison with the performance data collected during the intervention condition (with technology introduced). Secondary outcome measures will evaluate the impact of the intervention. The protocol includes 2 customizable Microsoft Excel spreadsheets for electronic record keeping.
RESULTS: Recruitment period is June 2022 through March 2024. Trial results for the individual participants will be graphed and analyzed separately using structured visual analysis supplemented with statistical analysis. Analysis will focus on important features of the data, including both within- and between-phase comparisons for response level, trend, variability, immediacy, consistency, and overlap. An exploratory economic evaluation will determine the impact on formal and informal support usage, together with quality of life, following the implementation of the new technological intervention.
CONCLUSIONS: The study has been designed to test the cause-effect functional relationships between the intervention-in this case, electronic assistive technology-and its effect in changing the target behavior(s). The evaluation evidence gained will offer new insights into the application of various electronic assistive technologies for people who experience executive dysfunction following ABI. Furthermore, the results will help increase the capacity of key stakeholders to harness the potential of technology to build independence and reduce the cost of care for this population.
BACKGROUND: Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12622000835741, https://www.anzctr.org.au/ACTRN12622000835741.aspx.
UNASSIGNED: DERR1-10.2196/48503.